TRCT
AIM

Tower Research Capital (TRC)’s AIM ImmunoTech AIM Stock Holding History

Tower Research Capital (TRC)’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.33K Hold
4,668
– – ﹤0.01% 4841
2026
Q1 		$2.73K Buy
4,668
+4,543
+3,634% +$4.6K ﹤0.01% 4425
2025
Q4 		$141 Buy
+125
New +$231 ﹤0.01% 5015
2025
Q2 		– Sell
-143
Closed -$1.75K – 5703
2025
Q1 		$1.75K Sell
143
-4
-3% -$64 ﹤0.01% 4650
2024
Q4 		$2.91K Sell
147
-6
-4% -$140 ﹤0.01% 4750
2024
Q3 		$4.12K Sell
153
-115
-43% -$3.83K ﹤0.01% 4666
2024
Q2 		$9.97K Buy
268
+86
+47% +$3.65K ﹤0.01% 4190
2024
Q1 		$8.56K Sell
182
-7
-4% -$290 ﹤0.01% 4000
2023
Q4 		$8.31K Buy
189
+180
+2,000% +$8.39K ﹤0.01% 4522
2023
Q3 		$420 Sell
9
-39
-81% -$2.4K ﹤0.01% 5569
2023
Q2 		$3.21K Buy
48
+29
+153% +$1.4K ﹤0.01% 5097
2023
Q1 		$1K Buy
19
+17
+850% +$881 ﹤0.01% 5745
2022
Q4 		$0 Hold
2
– – ﹤0.01% 6989
2022
Q3 		$0 Hold
2
– – ﹤0.01% 7028
2022
Q2 		$0 Hold
2
– – ﹤0.01% 7133
2022
Q1 		$0 Sell
2
-47
-96% -$4.05K ﹤0.01% 7240
2021
Q4 		$4K Buy
+49
New +$7.58K ﹤0.01% 5411
2021
Q3 		– Sell
-97
Closed -$21K – 6700
2021
Q2 		$21K Buy
+97
New +$20.8K ﹤0.01% 3868
2021
Q1 		– Sell
-125
Closed -$22K – 6102
2020
Q4 		$22K Buy
+125
New +$25K ﹤0.01% 3826
2016
Q1 		– Hold
0
– -$1K – 5877
2015
Q4 		– Hold
0
– – – 4392

Other funds holding AIM

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
CA
Continuum Advisory Eagle, Idaho $1.24B AUM 30.12% 1-Year Est. Return

Tower Research Capital (TRC)'s AIM Position: Q2 2026 in Review

Tower Research Capital (TRC) held its AIM ImmunoTech (AIM) position steady in Q2 2026 at 4,668 shares worth $1.33K. The position accounts for ﹤0.01% of the portfolio, ranked #4841.

Tower Research Capital (TRC) first reported a position in AIM in Q4 2020 and has held it in 19 quarters since. The position peaked at $22K in Q4 2020. 18 funds tracked by Wall St. Rank hold AIM as of Q2 2026.

  • Tower Research Capital (TRC) held 4,668 shares of AIM ImmunoTech worth $1.33K as of Q2 2026.
  • Tower Research Capital (TRC) left its AIM ImmunoTech share count unchanged in Q2 2026.
  • AIM ImmunoTech made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4841 holding.
  • Tower Research Capital (TRC) first reported a position in AIM ImmunoTech in Q4 2020 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s AIM ImmunoTech position peaked at $22K in Q4 2020.
  • 18 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.